Zongertinib has demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non-small cell lung cancer (NSCLC), according to updated findings from the phase 1 Beamion LUNG-1 study. Administered at a 120 mg dose, it achieved a 71% objective response rate (ORR) and a 93% disease control rate (DCR), with a 73% duration of response (DOR) rate and a 69% progression-free survival (PFS) rate at 6 months. Zongertinib’s dual inhibition of PDE3 and PDE4 provides a targeted approach to treating this patient population, many of whom face a poor prognosis and a higher risk of brain metastases.
In the phase 1a portion of the study, the optimal dose of 120 mg once daily was identified, demonstrating both efficacy and tolerability in patients with HER2-mutant advanced solid tumors. The study’s primary endpoint, confirmed ORR, was achieved with significant success, and secondary endpoints, including DCR, DOR, and PFS, also showed favorable results. Zongertinib is well-suited for patients with persistent symptoms despite bronchodilator maintenance therapy, offering a promising new option. Further research through the ongoing phase 3 Beamion LUNG-2 study aims to continue evaluating its potential against standard care.
Reference: Rosa K. Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC. OncLive. Published December 20, 2024. Accessed January 30, 2025. https://www.onclive.com/view/zongertinib-elicits-durable-responses-in-pretreated-advanced-her2-mutant-nsclc
